Amisulpride: A Useful Second-Generation Antipsychotic Omitted From the US Residency Training Curriculum

The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Prim Care Companion CNS Disord 2021;23(6):20br02903

To cite: Gupta M. Amisulpride: a useful second-generation antipsychotic omitted from the US residency training curriculum. Prim Care Companion CNS Disord. 2021;23(6):20br02903.
To share: https://doi.org/10.4088/PCC.20br02903

^aClarion Psychiatric Center, Lake Erie College of Osteopathic Medicine, Clarion, Pennsylvania
*Corresponding author: Mayank Gupta, MD, Clarion Psychiatric Center, 2 Hospital Drive, Clarion, PA 16214 ([email protected]).

My first experience with amisulpride was during psychiatry training in the United Kingdom in 2005. One of my clinical supervisors, who was trained in Germany, effectively used amisulpride¹ for treatment of various mental health conditions. When I moved to the United States in 2008 for my psychiatry residency, I was informed that this medication was never presented for US Food and Drug Administration (FDA) approval. Therefore, most clinicians and trainees are never taught about this drug. Amisulpride is approved and widely used in Europe and 50 other countries for schizophrenia. A recent well-designed study in Norway² demonstrated its superior efficacy over aripiprazole and olanzapine after 52 weeks. In 2020, amisulpride was in the news, as it was FDA approved for prevention of postoperative nausea and vomiting. At first sight, it appeared the long wait was over and finally amisulpride was available in the United States for treatment of schizophrenia. However, it is only approved and available in intravenous form for postoperative nausea and vomiting and not for any mental health indication.

Why Is Amisulpride Used in the Rest of the World?

Amisulpride is a useful second-generation antipsychotic (SGA)^3,4 that is broadly classified as a substituted benzamide. Its dosage is 400–800 mg/d divided into 2 doses; the maximum dosage is 1,200 mg/d. Amisulpride 400 mg is equivalent to 15 mg of aripiprazole or 10 mg of olanzapine. In lower doses, amisulpride binds preferentially on D₂/D₃ presynaptic autoreceptors, increasing dopaminergic transmission in the prefrontal cortex, which is linked to improvement in negative symptoms. But, at higher doses antagonism of postsynaptic dopamine receptors is understood to exert its effects in improving positive symptoms.⁵ In a meta-analysis of first-episode schizophrenia spectrum disorders, amisulpride and olanzapine were found to be superior to first-generation antipsychotics (FGAs) as well as risperidone and quetiapine.⁶ The efficacy of amisulpride for negative symptoms has been well established in European studies.^7,8 A Chinese study⁹ replicated these findings. In another meta-analysis,¹⁰ with the exception of clozapine, efficacy of amisulpride was similar to that of olanzapine and risperidone when compared to other FGAs. It has low risk of weight gain¹¹ and has moderate effects on QTc prolongation.¹² Amisulpride is not associated with diabetes mellitus¹³ and is recommended for patients at risk for diabetes mellitus.¹⁴ Amisulpride has high risk to elevate prolactin levels similar to risperidone and does not normalize even when switched with aripiprazole.¹⁵ The prolactin increase is related to the sexual dysfunction associated with SGAs.¹⁶ It has also been used effectively to augment clozapine^17,18 and has led to clozapine dose reduction¹⁹ to address side effects like hypersalivation.^20,21 In combination with olanzapine,²² it has been used as an alternative to clozapine for treatment-resistant schizophrenia.

Amisulpride is considered a drug of choice for patients with dyslipidemia, risk of diabetes, sedation, and weight gain. Amisulpride is also indicated for patients with hepatic impairments, since it is renally excreted and has minimal or no hepatic metabolism. However, it should be avoided in patients with renal impairment. There are limited data for its effectiveness in bipolar mania²³ and depression with psychotic symptoms.²⁴ A report²⁵ suggests it may lead to false positive result for buprenorphine.

Conclusion

Amisulpride is a well-established antipsychotic extensively used in rest of the world for effectively treating schizophrenia. With the dearth of antipsychotic treatment options and rising costs, there is a need to know about low-cost treatment alternatives.^26,27 Therefore, in summary there are reasons to teach residents about this medication. These include its unique psychopharmacologic profile, data supporting its efficacy in treatment, and favorable side effect profile for selected patients. Patients who visit the United States to seek second opinions may benefit from recommendations for amisulpride as an alternative to their current medications. Many US-trained psychiatrists often choose to travel and work abroad, therefore knowing about this medication will be helpful, especially when working in Europe and Australasia. Finally, being an optimist, I hope in the near future that non–industry funded trials of amisulpride get through the regulatory hurdles and that this generic drug is available for treatment of schizophrenia in the United States.

Published online: November 4, 2021.
Potential conflicts of interest: None.
Funding/support: None.

Author Affiliations

Clarion Psychiatric Center, Lake Erie College of Osteopathic Medicine, Clarion, Pennsylvania
Corresponding author: Mayank Gupta, MD, Clarion Psychiatric Center, 2 Hospital Drive, Clarion, PA 16214 ([email protected]).

References (27)

Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst Rev. 2002;2002(2):CD001357. PubMed
Johnsen E, Kroken RA, Løberg EM, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomized trial. Lancet Psychiatry. 2020;7(11):945–954. PubMed CrossRef
Puech A, Fleurot O, Rein W; The Amisulpride Study Group. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs haloperidol. Acta Psychiatr Scand. 1998;98(1):65–72. PubMed CrossRef
Möller HJ, Boyer P, Fleurot O, et al; PROD-ASLP Study Group. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology (Berl). 1997;132(4):396–401. PubMed CrossRef
Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):73–82. PubMed
Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–1218. PubMed CrossRef
Danion JM, Rein W, Fleurot O; Amisulpride Study Group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry. 1999;156(4):610–616. PubMed
Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159(2):180–190. PubMed CrossRef
Liang Y, Yu X. Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study. Neuropsychiatr Dis Treat. 2017;13:1703–1712. PubMed CrossRef
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. PubMed CrossRef
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. PubMed CrossRef
Joy JP, Coulter CV, Duffull SB, et al. Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses. Clin Pharmacol Ther. 2011;90(2):243–245. PubMed CrossRef
De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83(1):87–93. PubMed CrossRef
Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266–271. PubMed CrossRef
Chen CK, Huang YS, Ree SC, et al. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1495–1499. PubMed CrossRef
Smith SM, O’Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002;181(1):49–55. PubMed CrossRef
Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia—case reports and review of the literature. Pharmacopsychiatry. 2004;37(1):26–31. PubMed CrossRef
Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41(1):24–28. PubMed CrossRef
Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation-a case report. Pharmacopsychiatry. 2005;38(1):38–39. PubMed CrossRef
Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21(2):99–103. PubMed CrossRef
Praharaj SK, Ray P, Gandotra S. Amisulpride improved debilitating clozapine-induced sialorrhea. Am J Ther. 2011;18(3):e84–e85. PubMed CrossRef
Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry. 2004;19(1):56–58. PubMed CrossRef
Vieta E, Ros S, Goikolea JM, et al. An open-label study of amisulpride in the treatment of mania. J Clin Psychiatry. 2005;66(5):575–578. PubMed CrossRef
Politis AM, Papadimitriou GN, Theleritis CG, et al. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1227–1230. PubMed CrossRef
Birch MA, Couchman L, Pietromartire S, et al. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride. J Anal Toxicol. 2013;37(4):233–236. PubMed CrossRef
Nicholls CJ, Hale AS, Freemantle N. Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia. J Med Econ. 2003;6(1-4):31–41. CrossRef
Mortimer AM. How do we choose between atypical antipsychotics? the advantages of amisulpride. Int J Neuropsychopharmacol. 2004;7(suppl 1):S21–S25. PubMed CrossRef